We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multimillion Dollar Investment Launches Drug Development Research Startup

By LabMedica International staff writers
Posted on 28 Jun 2015
Print article
A global healthcare company with research and development interests in the area of pharmaceuticals, vaccines, and consumer healthcare will be financing an independent startup to promote drug development through advances in the understanding of gene function and control.

The biopharmaceutical company GlaxoSmithKline (London, United Kingdom) will be investing 95 million USD to launch the startup Altius Institute for Biomedical Sciences. Altius will be located in Seattle, WA, USA. The agreement is for 10 years of collaboration during which GlaxoSmithKline will have first rights to option inventions and products developed by Altius and to invest in commercialization of its discoveries via spinout companies. Additional funding from GlaxoSmithKline will be provided as necessary to tie technologies and discoveries made by Altius to a wide range of drug discovery and development projects.

“Dramatic breakthroughs in understanding how the human genome functions are still in their infancy in terms of how they can be applied to drug discovery, but we can see their potential to transform the process,” said Lon Cardon, senior vice president of alternative discovery and development at GlaxoSmithKline. “This is not an incremental change. We are aiming for transformative outcomes that could improve our ability to bring innovative and more effective new medicines to patients.”

Altius Institute for Biomedical Sciences is to be headed by Dr. John Stamatoyannopoulos, professor of genome sciences at the University of Washington (Seattle, USA). “With this visionary investment, GlaxoSmithKline is gaining a front-line view into the revolution now underway in understanding how cells function,” said Dr. Stamatoyannopoulos. “Innovative technologies are needed to gain a deeper understanding of how cells’ "operating systems" work.”

Related Links:

GlaxoSmithKline
University of Washington School of Medicine



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Automatic Biochemistry Analyzer
Audmax 180 Evolution
New
Auto-Chemistry Analyzer
CS-1200

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.